Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
60.3M
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
29.5M
-
Shares change
-
+659K
-
Total reported value, excl. options
-
$400M
-
Value change
-
+$8.92M
-
Number of buys
-
19
-
Number of sells
-
-12
-
Price
-
$13.54
Significant Holders of Janux Therapeutics, Inc. - Common Stock (JANX) as of Q3 2022
44 filings reported holding JANX - Janux Therapeutics, Inc. - Common Stock as of Q3 2022.
Janux Therapeutics, Inc. - Common Stock (JANX) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.5M shares
of 60.3M outstanding shares and own 48.97% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (8.67M shares), FMR LLC (6.25M shares), ORBIMED ADVISORS LLC (2.84M shares), JANUS HENDERSON GROUP PLC (1.96M shares), CITADEL ADVISORS LLC (1.85M shares), BVF INC/IL (1.47M shares), EcoR1 Capital, LLC (1.42M shares), BlackRock Inc. (1.25M shares), VANGUARD GROUP INC (760K shares), and 5AM Venture Management, LLC (446K shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.